Oncotelic Therapeutics Inc
OTC:OTLC
Income Statement
Earnings Waterfall
Oncotelic Therapeutics Inc
Revenue
|
70k
USD
|
Operating Expenses
|
-975.5k
USD
|
Operating Income
|
-905.5k
USD
|
Other Expenses
|
-11.6m
USD
|
Net Income
|
-12.5m
USD
|
Income Statement
Oncotelic Therapeutics Inc
Sep-2013 | Dec-2013 | Mar-2014 | Jun-2014 | Sep-2014 | Dec-2014 | Mar-2015 | Jun-2015 | Sep-2015 | Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||||||||||||||||||||||
Revenue |
0
N/A
|
0
-29%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
2
+412%
|
2
N/A
|
2
N/A
|
1
-20%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
Operating Income | ||||||||||||||||||||||||||||||||||||||||||
Operating Expenses |
(8)
|
(8)
|
(9)
|
(11)
|
(12)
|
(13)
|
(13)
|
(12)
|
(12)
|
(14)
|
(14)
|
(15)
|
(14)
|
(14)
|
(14)
|
(15)
|
(15)
|
(14)
|
(11)
|
(8)
|
(5)
|
(3)
|
(3)
|
(3)
|
(4)
|
(4)
|
(6)
|
(7)
|
(7)
|
(9)
|
(8)
|
(11)
|
(11)
|
(9)
|
(11)
|
(8)
|
(7)
|
(6)
|
(2)
|
(2)
|
(1)
|
|
Selling, General & Administrative |
(5)
|
(5)
|
(5)
|
(6)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(4)
|
(4)
|
(3)
|
(3)
|
(3)
|
(3)
|
(2)
|
(2)
|
(3)
|
(2)
|
(3)
|
(5)
|
(5)
|
(5)
|
(5)
|
(3)
|
(5)
|
(5)
|
(5)
|
(9)
|
(6)
|
(5)
|
(5)
|
(1)
|
(1)
|
(1)
|
|
Research & Development |
(3)
|
(4)
|
(4)
|
(6)
|
(7)
|
(7)
|
(8)
|
(8)
|
(8)
|
(9)
|
(9)
|
(10)
|
(9)
|
(9)
|
(10)
|
(10)
|
(11)
|
(10)
|
(8)
|
(5)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(4)
|
(6)
|
(6)
|
(6)
|
(4)
|
(3)
|
(2)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
|
Operating Income |
(8)
N/A
|
(8)
-5%
|
(9)
-9%
|
(11)
-25%
|
(12)
-7%
|
(13)
-5%
|
(13)
-1%
|
(12)
+5%
|
(12)
-1%
|
(14)
-11%
|
(14)
-4%
|
(15)
-2%
|
(14)
+2%
|
(14)
+4%
|
(14)
-5%
|
(15)
-2%
|
(15)
-2%
|
(14)
+7%
|
(11)
+23%
|
(8)
+28%
|
(5)
+37%
|
(3)
+38%
|
(3)
-6%
|
(3)
-8%
|
(4)
-7%
|
(4)
-16%
|
(6)
-39%
|
(5)
+20%
|
(6)
-14%
|
(8)
-38%
|
(7)
+8%
|
(11)
-54%
|
(11)
-2%
|
(9)
+17%
|
(11)
-25%
|
(8)
+31%
|
(7)
+15%
|
(6)
+16%
|
(2)
+73%
|
(2)
+1%
|
(1)
+40%
|
|
Pre-Tax Income | ||||||||||||||||||||||||||||||||||||||||||
Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(1)
|
(2)
|
(2)
|
(2)
|
(1)
|
15
|
14
|
14
|
14
|
(2)
|
(2)
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
(2)
|
(2)
|
(2)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
(0)
|
(4)
|
(4)
|
(10)
|
(10)
|
|
Total Other Income |
(0)
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
|
Pre-Tax Income |
(8)
N/A
|
(8)
-5%
|
(9)
-9%
|
(11)
-25%
|
(12)
-7%
|
(13)
-4%
|
(13)
-1%
|
(12)
+5%
|
(12)
-1%
|
(14)
-11%
|
(14)
-4%
|
(15)
-2%
|
(14)
+2%
|
(14)
+4%
|
(14)
-5%
|
(15)
-2%
|
(15)
-2%
|
(14)
+7%
|
(11)
+23%
|
(7)
+30%
|
(5)
+39%
|
(3)
+40%
|
(3)
-7%
|
(3)
-19%
|
(4)
-9%
|
(7)
-75%
|
(10)
-55%
|
(9)
+17%
|
(10)
-12%
|
(10)
-4%
|
(8)
+15%
|
(13)
-49%
|
(12)
+1%
|
(11)
+16%
|
(12)
-19%
|
7
N/A
|
8
+14%
|
5
-42%
|
9
+96%
|
(14)
N/A
|
(13)
+7%
|
|
Net Income | ||||||||||||||||||||||||||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Income from Continuing Operations |
(8)
|
(8)
|
(9)
|
(11)
|
(12)
|
(13)
|
(13)
|
(12)
|
(12)
|
(14)
|
(14)
|
(15)
|
(14)
|
(14)
|
(14)
|
(15)
|
(15)
|
(14)
|
(11)
|
(7)
|
(5)
|
(3)
|
(3)
|
(3)
|
(4)
|
(7)
|
(10)
|
(9)
|
(10)
|
(10)
|
(8)
|
(13)
|
(12)
|
(11)
|
(12)
|
7
|
8
|
5
|
9
|
(14)
|
(13)
|
|
Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
|
Net Income (Common) |
(13)
N/A
|
(13)
-3%
|
(14)
-6%
|
(14)
+2%
|
(12)
+11%
|
(13)
-4%
|
(13)
-1%
|
(12)
+5%
|
(12)
-1%
|
(14)
-11%
|
(14)
-4%
|
(15)
-2%
|
(14)
+2%
|
(14)
+4%
|
(14)
-5%
|
(15)
-2%
|
(15)
-2%
|
(14)
+7%
|
(11)
+23%
|
(7)
+30%
|
(5)
+39%
|
(3)
+40%
|
(3)
-7%
|
(3)
-19%
|
(4)
-9%
|
(7)
-75%
|
(10)
-55%
|
(9)
+17%
|
(10)
-12%
|
(10)
+1%
|
(8)
+19%
|
(11)
-50%
|
(11)
+4%
|
(9)
+15%
|
(11)
-22%
|
8
N/A
|
9
+10%
|
5
-41%
|
9
+85%
|
(13)
N/A
|
(12)
+7%
|
|
EPS (Diluted) |
-4.79
N/A
|
-4.67
+3%
|
-1.52
+67%
|
-0.78
+49%
|
-0.58
+26%
|
-0.75
-29%
|
-0.6
+20%
|
-0.45
+25%
|
-0.46
-2%
|
-0.54
-17%
|
-0.55
-2%
|
-0.56
-2%
|
-0.54
+4%
|
-0.51
+6%
|
-0.54
-6%
|
-0.55
-2%
|
-0.56
-2%
|
-0.52
+7%
|
-0.4
+23%
|
-0.18
+55%
|
-0.1
+44%
|
-0.07
+30%
|
-0.05
+29%
|
-0.05
N/A
|
-0.07
-40%
|
-0.11
-57%
|
-0.12
-9%
|
-0.09
+25%
|
-0.1
-11%
|
-0.11
-10%
|
-0.08
+27%
|
-0.03
+63%
|
-0.02
+33%
|
-0.03
-50%
|
-0.02
+33%
|
0.03
N/A
|
0.03
N/A
|
0.01
-67%
|
0.03
+200%
|
-0.03
N/A
|
-0.03
N/A
|